Boston Therapeutics, Inc.
BTHE
Other OTC0.01
USD
- -
- -
CIK
0001473579
ISIN
US1011501004
CUSIP
101150100
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Chi-Heng Cheng
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 354 Merrimack Street #4 Lawrence MA United States of America 01843
- IPO Date
- Mar 20, 2012
- CIK
- 0001473579
- Website
- bostonti.com
- Similar Companies
- Business
- Boston Therapeutics, Inc. (BTHE) develops, manufactures, and commercializes pharmaceutical compounds targeting diabetes and inflammatory diseases through its focus on glyco-pathology. The company offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary supplement designed to support healthy blood glucose levels by blocking carbohydrate-hydrolyzing enzymes in the gastrointestinal tract; BTI-320 (formerly PAZ320), a chewable non-systemic therapeutic compound that reduces post-meal glucose elevation in type 2 diabetes patients; and IPOXYN, an injectable anti-necrosis drug in pre-clinical development for lower limb ischemia associated with diabetes. Founded in 2009 and headquartered in Lawrence, Massachusetts, with operations referenced in Manchester, New Hampshire, Boston Therapeutics targets patients with metabolic disorders primarily in the United States. The company maintains a lean structure with no reported institutional ownership and limited recent funding or partnerships, while its product pipeline remains centered on advancing clinical-stage carbohydrate chemistry innovations amid ongoing low revenue and net losses. No major acquisitions, strategic alliances, new product launches, or operational shifts have been announced in the last 1-2 years.